A collection of presentations from the 2021 ASH Annual Meeting, selected by Novartis

Featuring licensed content from

vlcsnap-2021-12-13-09h14m23s319
Oral Session
Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Presenter: Michael R. Bishop, MD
Date: December 14, 2021
Abstract Number: LBA-6
Indication: DLBCL/FL/ALL/MM
885
Oral Session
Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry
Presenter: Roberta Di Blasi, MD, PhD
Date: December 13, 2021
Abstract Number: 885
Indication: DLBCL/FL/ALL/MM
3864
Poster Session
Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-ChargeTM Platform
Presenter: Adam S. Sperling, MD, PhD
Date: December 13, 2021
Abstract Number: 3864
Indication: DLBCL/FL/ALL/MM
428
Oral Session
Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Presenter: Samuel John, MD
Date: December 12, 2021
Abstract Number: 428
Indication: DLBCL/FL/ALL/MM
429
Oral Session
Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin’s Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Presenter: Daniel J Landsburg, MD
Date: December 12, 2021
Abstract Number: 429
Indication: DLBCL/FL/ALL/MM
131
Oral Session
Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study
Presenter: Catherine Thieblemont, MD, PhD
Date: December 11, 2021
Abstract Number: 131
Indication: DLBCL/FL/ALL/MM
740
Oral Session
A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-ChargeTM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Presenter: Ian W. Flinn, MD, PhD
Date: December 13, 2021
Abstract Number: 740
Indication: DLBCL/FL/ALL/MM
2173
Poster Session
12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Presenter: Jun Ho Jang, MD, PhD
Date: December 12, 2021
Abstract Number: 2173
Indication: PNH
2174
Poster Session
Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study
Presenter: Carlos Vallejo, MD, PhD
Date: December 12, 2021
Abstract Number: 2174
Indication: SAA
3113
Poster Session
Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study
Presenter: Julie Kanter, MD
Date: December 13, 2021
Abstract Number: 3113
Indication: SCD
490
Oral Session
Frequency of Vaso-Occlusive Crises Is Associated with Health-Related Quality of Life in Pediatric Patients with Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers
Presenter: Andrew D. Campbell, MD
Date: December 12, 2021
Abstract Number: 490
Indication: SCD
3112
Poster Session
Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events during or after Crizanlizumab Infusion in Patients (Pts) with Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports
Presenter: Julie Kanter, MD
Date: December 13, 2021
Abstract Number: 3112
Indication: SCD
2032
Poster Session
Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab across Cell Adhesion Assays in Vitro
Presenter: Prithu Sundd, PhD
Date: December 12, 2021
Abstract Number: 2032
Indication: SCD
12
Oral Session
Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)
Presenter: Matthew M. Heeney, MD
Date: December 11, 2021
Abstract Number: 12
Indication: SCD
1478
Poster Session
Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase
Presenter: Jorge E. Cortes, MD
Date: December 11, 2021
Abstract Number: 1478
Indication: CML
310
Oral Session
Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks
Presenter: Michael J. Mauro, MD
Date: December 11, 2021
Abstract Number: 310
Indication: CML
1303
Poster Session
Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial
Presenter: Jacqueline J Cloos, MD, PhD
Date: December 11, 2021
Abstract Number: 1303
Indication: MDS/AML
3417
Poster Session
Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subset Analysis of Safety and Preliminary Efficacy
Presenter: Eytan M. Stein, MD
Date: December 13, 2021
Abstract Number: 3417
Indication: MDS/AML
1283
Poster Session
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)
Presenter: Andrew H. Wei, MBBS, PhD
Date: December 11, 2021
Abstract Number: 1283
Indication: MDS/AML
2605-cover
Poster Session
Treatment Patterns and Overall Survival in Patients with Intermediate-Risk MDS: A Retrospective Analysis in the Spanish MDS Registry
Presenter: María Diez-Campelo, MD, PhD
Date: December 12, 2021
Abstract Number: 2605
Indication: MDS/AML
244-cover
Oral Session
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
Presenter: Andrew M. Brunner, MD
Date: December 11, 2021
Abstract Number: 244
Indication: MDS/AML
3909-cover
Poster Session
Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)
Presenter: Stephanie Lee, MD, MPH
Date: December 13, 2021
Abstract Number: 3909
Indication: MPN/GvHD

Accessing this content will consume 1 of your  3 remaining content items.  

Are you sure you wish to proceed?

Proceed
Cancel
To access this collection, please read through and accept any terms and conditions and confirm that you are a healthcare professional.

By accessing this collection you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • Residents of the United States will need to provide a full validated registration
  • Residents of the United States will have their use of the content tracked and reported for Transfer of Value (ToV) reporting purposes 
  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorized duplication or unauthorized distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
© 2022 American Society of Hematology. All rights reserved. ASH® and the ASH logo are registered trademarks of the American Society of Hematology. Used with permission.
This web site is provided for informational purposes and personal use only, and is not intended to provide medical advice, diagnosis, or treatment or for commercial use. The ideas and opinions expressed herein do not necessarily reflect those of the American Society of Hematology (ASH®). The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.